LA MIRADA, CA--(Marketwire - August 24, 2011) - BioLargo, Inc. (OTCBB: BLGO), creator of patented iodine technologies, today announced that medical products expert Tim R. Johnson has joined its team to assist the company in developing and exploiting its commercial opportunities for the BioLargo Technology within the medical industry.
Mr. Johnson's history and experience in the medical products field is extensive. In 1991, he began his career as a Market Specialist and Sales Manager with Fortune 100 medical product firm Merck & Co, Inc. In 1995, Tim began work for a major Swiss medical device manufacturer, Medela, Inc., as their International Sales Manager. In 2002 he co-founded a medical equipment manufacturer focused on negative pressure advanced wound care therapeutic devices, Blue Sky Medical Group. He organized and supervised multiple departments, including sales, clinical support, operations and distributors. He developed multiple products and was responsible for acquiring components used in the company's devices. His work and the company's commerical success led to a sale of the business to Smith & Nephew in 2007. After selling his device company, he founded a consulting company focusing on assisting medical device companies in sales and marketing, business development, clinical education, product design, research and development, and operations management. In 2008 he was part of the founders group and worked with Hygeia II Medical Group, Inc. as VP of Integration, International/Regional Sales Manager, and Special Liaison to the Board of Directors and consultant selling medical products into acute care, government, public health and retail sectors of the market.
"Tim brings to BioLargo a wealth of practical experience in developing clinical products and selling into the medical industry. Our BioLargo Technology was first discovered by our Inventor and CTO Kenneth Reay Code in his successful personal journey to help keep his father safe from nosocomial infections, which are prevalent in extended care or nursing homes. Since then we have advanced the science, patents and proofs of claims to the point where we are able to develop specific products that solve unmet needs in the marketplace. Tim will develop relationships with supply-chain partners within the medical industry to take advantage of the significant commercial opportunities that exist for our non-toxic, non-staining version of iodine based products. Tim is a proven winner and we are glad he has joined us in this important work," stated BioLargo President and CEO, Dennis P. Calvert.
About BioLargo, Inc.
BioLargo's business strategy is to harness and deliver Nature's Best Solution™ -- free-iodine -- in a safe, efficient, environmentally sensitive and cost-effective manner. BioLargo's proprietary technology works by combining micro-nutrient salts with liquid from any source to deliver free-iodine on demand, in controlled dosages, in order to balance efficacy of performance with concerns about toxicity. BioLargo's technology has potential commercial applications within global industries, including but not limited to oil and gas, animal health, beach and soil environmental uses, consumer products, agriculture, food processing, medical, and water. It features solutions for odor & moisture control, disinfection and contaminated water treatment. The company's website is www.BioLargo.com. In 2010, Odor-No-More was awarded two Editor's Choice Awards, including a "Product of the Year" award, by the Horse Journal, a top industry award for excellence and are sold by BioLargo's wholly owned subsidiary, Odor-No-More, Inc. (www.OdorNoMore.com). In early 2011, the company signed an exclusive license agreement for use in pet products with industry leader Central Garden and Pet.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in the BioLargo's Annual Report on Form 10-K for the year ended December 31, 2010.